Aris Global announced that invivodata has been selected as its preferred partner for ePRO solutions.
invivodata’s ePRO solutions–DiaryPRO® for field-based data collection and SitePRO® for in-clinic based data collection – will provide complementary functionality to Aris Global’s Total Clinical™ suite of integrated solutions, which includes agCapture™ for electronic data capture, ARISg™ for drug safety, agXchange and agClinical™ for clinical trial management. Total Clinical enables companies to enter data once and share across their enterprise. The Total Clinical suite is available on a hosted, managed platform and includes a full range of delivery and support services.
Aris Global’s strategy is to partner with solution providers currently serving the growing ePRO market. invivodata’s ePRO solutions are consistent with Aris Global’s standards of customer service.
“We are very excited about our partnership with invivodata,” said Dr. Sylva H. Collins, vice president, Total Clinical Solutions at Aris Global. “The use of invivodata’s ePRO system brings scientific and regulatory credibility in capturing the patient’s experience in a clinical trial.” “Aris Global’s Total Clinical suite offers value to clinical researchers,” said Doug Engfer, president and CEO at invivodata. “We look forward to working with them and aligning our eClinical solutions to further help life science organizations meet regulatory guidelines, manage risk and improve operational efficiencies.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.